MNPR Monopar Therapeutics Inc: Earnings per share for the last 12 months

Monopar Pharma (MNPR) - corporate logo

Monopar Therapeutics (MNPR) risks are tied to the outcomes of primary radiopharmaceutical agent tests, which requires management to strictly monitor capital expenditure. A network of global laboratories ensures supply stability for the clinic, guaranteeing future profits. This price chart reflects the market trend of the asset with the 25.10 indicator, complementing the profile of the company, which develops methods to combat chemotherapy toxicity and progressive forms of malignant neoplasms.

Monopar Pharma (MNPR) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/17/2026

MNPR (Monopar Therapeutics Inc): analytical breakdowns and indicator data

Fundamental company valuation:MNPR Monopar Pharma
Flagship merchandise of Monopar Therapeutics Inc.

For the asset-light model of Monopar Therapeutics (MNPR), which delegates the production of oncology drugs to external contractors, the TTM net income per share annual growth trend serves as an indicator of operational efficiency. This metric measures the dynamics of the rolling annual profit growth by comparing current results with historical data. The calculation is based on the difference in EPS over the last twelve months relative to the same period last year. Sharp spikes in the line without volume confirmation may signal a false breakout with a risk of correction.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months